乳液法静电纺丝PLGA组织工程缓释纤维的研究

目的：研究Dextran对蛋白药物的释放影响。方法：将模型蛋白BSA溶解于多糖溶液中,通过W/O乳液法静电纺丝制备缓释纤维。采用MicroBCA法测定该纤维体外释放行为,采用SEC-HPLC检测制备前后蛋白的聚集程度,并与不含多糖的BSA纤维做对照。结果：添加Dextran以后蛋白的包封率由52.68%提高到63.92%,第一天突释不大于药物载量的15%,对蛋白单体的保持达到85%以上。结论：Dextran可以改善一般组织工程纤维中蛋白药物的释放,提高蛋白药物在制剂、贮存、释放过程中的稳定性,增加纤维的载药量。     

静电纺丝纳米纤维体外释放与蛋白活性的研究

目的:通过选择不同的模型蛋白,探讨准确的研究静电纺丝纳米纤维支架的体外释放和快速的测定蛋白活性的方法.方法:通过O/W乳液法静电纺丝制备纳米纤维,并用扫描电镜对纳米纤维表面进行了表征.以GM-CSF为模型蛋白,采用ELISA双抗体夹心法考察纤维的体外释放行为;以BSA为模型蛋白,用SEC-H-PLC比较纤维制备前后蛋白的聚集情况;以β-半乳糖苷酶为模型蛋白,用ONPG法比较纤维制备前后酶的催化活性.结果:纤维表面平滑,直径均一,呈现互相连通的三维网状结构.纤维在5天内释放90％以上;纤维中回收的BSA单体比例为66.53％;β-半乳糖苷酶在纤维中的催化活性保持原活性的3.37％.结论:通过选择不同的模型蛋白,能够准确的测定静电纺丝纤维的体外释放,快速的考察纤维中的蛋白活性,对于更好的研究蛋白药物纳米纤维支架具有重要的参考价值.     

包裹于PLGA微球中用于蛋白控释的多糖纳米颗粒

目的:研究包裹在PLGA微球中的多糖纳米颗粒在保护蛋白稳定性和改善药物体外释放行为方面的作用。方法:将模型药物BSA用低温诱导相分离方法担载于多糖纳米颗粒之中,后将其用水包油包固复乳法包裹于PLGA微球内。应用体积排阻色谱(SEC-HPLC)和红外色谱(FTIR)表征蛋白的稳定性,而且也研究了样品的体外释放行为。结果:这种方法能够很好的保护蛋白的稳定性,保持蛋白结构在制备过程中不会改变,而且改善了体外释放行为,减少了突释。结论:多糖纳米颗粒结合PLGA微球能够提供一种有效的解决蛋白控释的途径。     

聚乙烯醇/葡聚糖复合凝胶的制备及药物释放规律的研究

目的:采用冷冻-解冻物理交联方法制备聚乙烯醇(PVA)和葡聚糖(Dextran)混合凝胶.并考察复合凝胶药物释放规律.方法:含有胰岛素的PVA/Dextran溶液置于-20℃条件下冷冻8 h,在室温下解冻4 h,反复冷冻-解冻数次制备得到胰岛素PVA/Dextran复合凝胶,反相高效液相色谱法考察了胰岛素的体外释放行为.结果:胰岛素复合凝胶体外释放模式符合Higuchi扩散方程.当PVA/Dextran比例从100/0降到80/20,胰岛素释放速率明显增加,最大释放率从45%增加到65%.当冷冻-解冻循环次数从2增加到6,胰岛素达到最大释放的时间从24 h增加到45 h,最大释放率从70%降到50%.释放介质的温度的升高能显著增加胰岛素的释放速率.结论:PVA/Dextran制备的胰岛素复合凝胶具有良好的缓释效果.PVA/Dextran复合凝胶是一种较有前景的水凝胶药物载体.     

多糖颗粒复合PLGA微球用于脉冲式释药系统的研究

目的:考察多糖颗粒复合PLGA微球用作脉冲式释药系统的可行性.方法:用水相-水相乳化法将模型蛋白BSA包裹于多糖颗粒中,再用S/O/W法制备多糖颗粒复合PLGA微球.采用microBCA法测定该微球体外释放行为,并与W/O/W复乳法制备的BSA微球相对照.结果:用W/O/W复乳法制备的BSA微球的体外释放曲线显示,该微球在开始释放第一天起就出现一个平台期,之后则产生一个持续高释放量的行为.而多糖颗粒复合PLGA微球的体外释放曲线显示,其在释放第一天和一个较长平台期之后都出现峰形释放,相对于前者微球与脉冲释药模式更为相近.平台期时长与高分子性质有关,PLGA结构中乳酸相对于乙醇酸比例越高则平台期越长.结论:多糖颗粒复合PLGA微球具有良好的脉冲式释药效果,是一种较有前景的脉冲释药系统.     

PLGA微球复合明胶组织工程支架缓释蛋白药物的研究

目的：研究PLGA微球复合明胶支架对蛋白药物的释放影响。方法：将模型蛋白BSA通过复乳法制备成缓释PLGA微球,然后将微球埋置于明胶支架中,形成担载蛋白的PLGA微球复合明胶组织工程支架。考察复合支架体外蛋白释放行为,并用MicroBCA法定量测定释放的BSA量,采用β-半乳糖苷酶催化ONPG的方法检测制备前后蛋白的活性,并与不含PLGA微球直接担载蛋白的支架做对照。结果：PLGA微球复合支架蛋白的包封率能达到73．2％,其中第一天释放20％,对蛋白活性的保持达到70％以上。结论：微球复合明胶支架可以改善一般组织工程支架蛋白药物的突释,提高蛋白药物在制剂,贮存,释放过程中的稳定性。     

蛋白药物涂层支架的制备表征与体外释放研究

目的:探讨将蛋白大分子药物以较高的担载量涂层于心脏支架,并在不发生蛋白聚集的前提下实现数周之久缓释的方法.方法:将牛血清白蛋白通过稳定的水相-水相乳液技术制备成多糖玻璃体颗粒,并将多糖玻璃体颗粒分散于聚乳酸溶液中喷涂于支架表面制成蛋白涂层支架,在37°CPBs中进行体外释放动力学研究,用SEC-HPLC比较了蛋白涂层支架制备前后蛋白的聚集情况,并用扫描电镜等对蛋白涂层支架表面进行了表征.结果:蛋白涂层支架在电镜观察下外观圆整,表面光滑,制剂过程中未产生蛋白聚集,且能从涂层中缓慢释放达50天以上.结论:稳定的水相-水相乳液技术及其基础上制备的蛋白多糖玻璃体颗粒应用于心脏支架涂层上,能在有效保护蛋白构象的同时实现蛋白的缓释,为具有抗再狭窄活性蛋白应用于心脏支架提供了技术平台.     

氢氧化镁调控BSA-PLGA微球体外释放的研究

目的:探索氢氧化镁对BSA微球体外释放的影响,优化BSA微球的制备工艺。方法:通过水包油包固复乳法制备BSA-PLGA微球。先将BSA与葡聚糖制备成玻璃体颗粒,再将玻璃体颗粒与氢氧化镁包裹进PLGA中,制备成缓释微球。在扫描电镜下观察其形态。然后用Micro BCA法测定其包封率和载药量,并考察其体外释放行为。结果:所制得的微球粒径约60μm,呈较好的球形。添加氢氧化镁后,BSA微球的包封率和载药量都有显著提高。不同含量的氢氧化镁对BSA微球的包封率和载药量影响也不同。在体外释放过程中,载有氢氧化镁的微球14天累积释放量为(85.10±2.67)%,而对照组不到80%。结论:通过调整氢氧化镁的量,可以制得形态完整,大小均匀,突释较小的BSA微球。     

叶酸介导的普鲁兰多糖- 阿霉素聚合物前药的制备及生物学性能初探

目的:制备叶酸介导的普兰多糖-阿霉素聚合物前药(FA-MP-DOX),实现阿霉素药物的靶向控制释放。方法:将普鲁兰多糖用马来酸酐进行修饰后,通过酰胺键键合阿霉素制备得到普鲁兰多糖-阿霉素(MP-DOX),继而酯键键合叶酸制备得到叶酸介导的普鲁兰多糖-阿霉素聚合物前药(FA-MP-DOX)。红外光谱、核磁共振光谱表征聚合物药物的结构,动态透析法模拟体外释药特性,监测不同pH值聚合物药物中阿霉素的释药特性,同时采用人口腔表皮样癌细胞(KB细胞)测定聚合物药物体系的细胞毒性。结果:①经核磁共振表征FA-MP-DOX聚合物合成完成。②在pH2.5、pH5.0及pH7.4的PBS缓冲体系16h中,阿霉素药物累积释放率分别为49.1%,30.3%和15.3%,证实FA-MP-DOX中阿霉素的释放具有pH依赖性。③细胞实验证实FA-MP-DOX的细胞毒性高于阿霉素和MP-DOX。结论:FA-MP-DOX聚合物药物有望成为阿霉素智能型控释和靶向性药物载体。     

叶酸介导的普鲁兰多糖-阿霉素聚合物前药的制备及生物学性能初探

目的：制备叶酸介导的普兰多糖-阿霉素聚合物前药（FA-MP-DOX）,实现阿霉素药物的靶向控制释放。方法：将普鲁兰多糖用马来酸酐进行修饰后,通过酰胺键键合阿霉素制备得到普鲁兰多糖-阿霉素（MP-DOX）,继而酯键键合叶酸制备得到叶酸介导的普鲁兰多糖-阿霉素聚合物前药（FA-MP-DOX）。红外光谱、核磁共振光谱表征聚合物药物的结构,动态透析法模拟体外释药特性,监测不同pH值聚合物药物中阿霉素的释药特性,同时采用人口腔表皮样癌细胞（KB细胞）测定聚合物药物体系的细胞毒性。结果：①经核磁共振表征FA-MP-DOX聚合物合成完成。②在pH2.5、pH5.0及pH7.4的PBS缓冲体系16h中,阿霉素药物累积释放率分别为49.1%,30.3%和15.3%,证实FA-MP-DOX中阿霉素的释放具有pH依赖性。③细胞实验证实FA-MP-DOX的细胞毒性高于阿霉素和MP-DOX。结论：FA-MP-DOX聚合物药物有望成为阿霉素智能型控释和靶向性药物载体。     

Emulsan, a tailorable biopolymer for controlled release

Microsphere hydrogels made with emulsan-alginate were used as carrier for the microencapsulation of blue dextran in order to study the effect of emulsan on the alginate bead stability. Blue dextran release studies indicated an increase of microsphere stability in presence of emulsan, as a coating agent. BSA adsorption by emulsan-alginate microspheres is also enhanced 40% compared to alginate alone. XPS studies confirm the presence of BSA adsorbed on emulsan microsphere surfaces. These results are in agreement with the equilibrium adsorption model of Freundlich. Studies of BSA adsorption using non-equilibrium Lagergren second-order and intraparticle models, are suggesting a complex mechanisms of protein adsorption by chemisorption and intraparticle diffusion. Also, enzymatic release of BSA from emulsan microspheres containing azo-BSA under physiological conditions is suggests the possibility of using microspheres as a depot for pre-proteins of medical interest.     

Determinants of atrial natriuretic factor secretion in dogs expanded with isotonic saline or colloid solutions.

Through increments in blood volume and atrial pressure are thought to be the primary stimuli for ANF secretion, plasma levels of this peptide do not always behave as a simple function of volume status. To outline the relationship between the latter and cardiac ANF release, we used five different volume-expansion protocols in anesthetized dogs. A stepwise expansion of plasma volume (PV) was achieved by two consecutive infusions: 0.9% saline followed or preceded by 4 or 25% bovine serum albumin (BSA), 4 or 25% dextran (Dx), or homologous plasma. Saline expansion led to a two- to four-fold increase in arterial plasma ANF level in all five protocols. Both 4 and 25% BSA caused no or very modest increase in plasma ANF, while all other colloid expanders caused the expected ANF release. In all protocols, plasma ANF closely correlated with central venous pressure (CVP). BSA expansion was the only protocol with no correlation between PV and ANF release. Changes in serum Ca2+ could not explain this finding. During BSA expansion, the lack of atrial response was related to the absence of increment (or even fall) in CVP despite the expanded PV. Similarly, urinary Na+ excretion was correlated both with CVP and ANF level but not with PV in BSA expansion. When the dogs were depleted of histamine before BSA infusion, the atrial secretory response was restored, suggesting that this colloid was associated with augmented capillary leakiness and vascular fluid efflux. These results show that the expansion of PV leads neither to ANF release nor to Na+ excretion if it is not accompanied by an expanded central blood volume with elevated atrial pressure.     

Molecular characteristics of bovine serum albumin-dextran conjugates

Bovine serum albumin (BSA)-dextran conjugates were prepared by using the Maillard reaction; depending on the ratio of dextran to BSA used, about 0.5-1 mol of dextran could be bound to 1 mol of native BSA. SDS-PAGE patterns revealed that BSA and dextran had been covalently bonded. Structural analyses by fluorescence spectroscopy and circular dichroism indicated that the BSA surface in each conjugate was covered with dextran without any great disruption of the native conformation. The conjugates could be grouped into two fractions on the basis of the weight-average molecular mass measured: the main fraction at 1.95-2.35 x 10(5) g/mol and a less-abundant fraction with aggregates greater than 1.50 x 10(6) g/mol. High-performance size-exclusion chromatography in conjunction with multi-angle laser light scattering detection revealed that the BSA-dextran conjugates prepared by using the Maillard reaction had various molar masses and radii.     

牛血清白蛋白在聚乙二醇/葡聚糖双水相体系中分配特性的研究

采用考马斯亮蓝G250染色法测得室温下BSA在PEG/dextran双水相体系中的分配系数。以BSA在PEG/dextran体系的下相富集为目标,研究了PEG的分子量、浓度、dextran浓度以及所加入中性盐的种类与浓度、体系pH诸因素对其分配特性的影响。实验结果表明,在PEG4000/dextran体系中,采用PEG质量分数9%-dextran质量分数9%的浓度组成,同时在pH=7.0,NaC l浓度为0.2 mol.L-1或pH6.0,NaC l浓度为0.34 mol.L-1的工艺条件下萃取BSA均可达最小分配系数,其值为0.014。     

Preparation and characterization of temperature-sensitive poly(N-isopropylacrylamide)-b-poly(D,L-lactide) microspheres for protein delivery

Temperature-sensitive diblock copolymers, poly(N-isopropylacrylamide)-b-poly(D,L-lactide) (PNIPAAm-b-PLA) with different PNIPAAm contents were synthesized and utilized to fabricate microspheres containing bovine serum albumin (BSA, as a model protein) by a water-in-oil-in-water double emulsion solvent evaporation process. XPS analysis showed that PNIPAAm was a dominant component of the microspheres surface. BSA was well entrapped within the microspheres, and more than 90% encapsulation efficiency was achieved. The in vitro degradation behavior of microspheres was investigated using SEM, NMR, FTIR, and GPC. It was found that the microspheres were erodible, and polymer degradation occurred in the PLA block. Degradation of PLA was completed after 5 months incubation in PBS (pH 7.4) at 37 degrees C. A PVA concentration of 0.2% (w/v) in the internal aqueous phase yielded the microspheres with an interconnected porous structure, resulting in fast matrix erosion and sustained BSA release. However, 0.05% PVA produced the microspheres with a multivesicular internal structure wrapped with a dense skin layer, resulting in lower erosion rate and a biphasic release pattern of BSA that was characterized with an initial burst followed by a nonrelease phase. The microspheres made from PNIPAAm-b-PLA with a higher portion of PNIPAAm provided faster BSA release. In addition, BSA release from the microspheres responded to the external temperature changes. BSA release was slower at 37 degrees C (above the LCST) than at a temperature below the LCST. The microspheres fabricated with PNIPAAm-b-PLA having a 1:5 molar ratio of PNIPAAm to PLA and 0.2% (w/v) PVA in the internal aqueous phase provided a sustained release of BSA over 3 weeks in PBS (pH 7.4) at 37 degrees C.     

Molecular Characteristics of Bovine Serum Albumin-Dextran Conjugates

Bovine serum albumin (BSA)-dextran conjugates were prepared by using the Maillard reaction; depending on the ratio of dextran to BSA used, about 0.5–1 mol of dextran could be bound to 1 mol of native BSA. SDS–PAGE patterns revealed that BSA and dextran had been covalently bonded. Structural analyses by fluorescence spectroscopy and circular dichroism indicated that the BSA surface in each conjugate was covered with dextran without any great disruption of the native conformation. The conjugates could be grouped into two fractions on the basis of the weight-average molecular mass measured: the main fraction at 1.95–2.35×10⁵ g/mol and a less-abundant fraction with aggregates greater than 1.50×10⁶ g/mol. High-performance size-exclusion chromatography in conjunction with multi-angle laser light scattering detection revealed that the BSA-dextran conjugates prepared by using the Maillard reaction had various molar masses and radii.     

How does dextran sulfate prevent heat induced aggregation of protein? The mechanism and its limitation as aggregation inhibitor

The effect of dextran sulfate on protein aggregation was investigated to provide the clues of its biochemical mechanism. The interaction between dextran sulfate and BSA varied with the pH values of the solution, which led to the different extent of aggregation prevention by dextran sulfate. Light scattering data with thermal scan showed that dextran sulfate suppressed BSA aggregation at pH 5.1 and pH 6.2, while it had no effect at pH 7.5. Isothermal titration calorimetric analysis suggested that the pH dependency of the role of dextran sulfate on BSA aggregation would be related to the difference in the mode of BSA-dextran sulfate complex formation. Isothermal titration calorimetric analysis at pH 6.2 indicated that dextran sulfate did not bind to native BSA at this pH, but interacted with partially unfolded BSA. While stabilizing native form of protein by the complex formation has been suggested as the suitable mechanism of preventing aggregation, our observation of conformational changes by circular dichroism spectroscopy showed that strong electrostatic interaction between dextran sulfate and BSA rather facilitated the denaturation of BSA. Combining the data from isothermal titration calorimetry, circular dichroism, and dynamic light scattering, we found that the complex formation of the intermediate state of denatured BSA with dextran sulfate is a prerequisite to suppress the aggregation by preventing further oligomerization/aggregation process of denatured protein.